Donor lymphocyte infusions (DLI) have been shown to enhance the graft-versus-leukaemia (GVL) effect and induce haematological and molecular remission in patients with relapsed CML following allogeneic bone marrow transplantation (BMT). The potent donor cellmediated cytolysis following DLI may lead to a short period of aplasia before the re-establishment of donor haematopoiesis. The absence of detectable donor cells in patients prior to DLI infusion may result in permanent aplasia in certain patients. We report on four patients who relapsed 1, 3, 6.5 and 7 years post-BMT for chronic phase CML and were treated with DLI from their original BMT donor. Polymorphic short tandem repeats (STRs) were used to assess haematological chimaerism both prior to and following DLI. At the time of relapse, STR-PCR indicated the presence of donor cells in all four patients, at levels ranging from 1-40%. A clinical and molecular response was seen in 4/4 patients following a short period of cytopenia and all patients remain in clinical remission with a follow-up of 2 months-3 years post-DLI. STR-PCR indicated that a response was occurring during the period of pancytopenia when metaphase analysis was unsuccessful. Lineage-specific analysis of the cellular response to DLI was monitored using STR-PCR of peripheral blood (PB) and bone marrow (BM) lymphocyte-enriched fractions and CD2-positive and -negative T cell fractions. In one patient BM and PB CD34-positive and -negative fractions were also assessed. A change in the ratio of donor:recipient cells in the PB lymphocyte fraction was the earliest molecular indication of an anti-leukaemic response. Subsequent conversion to donor chimaerism occurred in the other lineages and the granulocyte fraction was the last lineage to convert. In conclusion, lineage-specific STR-PCR permits detailed monitoring of subtle changes in donor/recipient cell dynamics in specific lineages following DLI during the crucial pancytopenic phase and may be a useful predictor of haematological response to DLI therapy.
cyte infusions (DLI); chimaerism; lineage-specific chimaerism; immunotherapy Allogeneic bone marrow transplantation (BMT) is the best therapeutic option for patients with chronic myeloid leukaemia (CML). Following BMT for CML, there is a strong anti-leukaemic effect which is thought to be mediated by donor T cells present in the bone marrow inoculum. 1, 2 This graft-versus-leukaemia (GVL) reaction is important in eradicating residual disease and establishing complete donor chimaerism in the recipient. Relapse rates of 10-20% occur in patients transplanted in chronic phase with unmanipulated BMT while patients receiving T cell-depleted marrow have higher rates of relapse. 2, 3 The clinical use of donor leucocyte infusions (DLI) to treat leukaemia relapse post-BMT has been shown to induce a potent anti-leukaemic effect which has resulted in haematological/molecular remission in 75-80% of CML patients who relapse post-BMT. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However there are two major causes of morbidity and mortality following DLI therapy; the occurrence of acute or chronic GVHD and/or the development of irreversible aplasia. DLI given in molecular or cytogenetic relapse, when haematopoiesis is maintained predominantly by donor cells, can result in a beneficial GVL response without the development of aplasia. 11, 13 However, the minimal reserve of donor cells required is unknown. In addition, the detection of donor cells of a particular cell lineage may be important in predicting a successful response. The aims of this study were (1) to measure the degree of donor chimaerism and its relevance prior to DLI; (2) to monitor changes in the chimaeric profile during the pancytopenic phase in an effort to identify if particular haemopoietic lineages can provide early molecular indication of a therapeutic response.
Patients and methods

Patients
All four patients received a BMT for chronic phase CML. Patient details are given in Table 1 . UPN 011/86 presented with an EBV-related laryngeal lymphoma 5.5 years post-BMT which responded to chemotherapy as described previously.
14 A haematological relapse occurred at 6.5 years 712 Patients were assessed clinically and haematologically with full blood and differential counts at least weekly until they responded. Bone marrow was obtained pre-DLI and at intervals post-DLI.
Methods
Cytogenetics/fluorescent in situ hybridisation (FISH):
Chimaerism was assessed using standard karyotypic analysis and/or fluorescent in situ hybridisation (FISH). The directly labelled fluorescent X and Y chromosome probes (Cytocell, Banbury, UK) were used according to the manufacturer's recommendations. The X probe is labelled with fluorescein (green) and the Yq probe with Cy3 (red). Where possible 200 nuclei were assessed using a rhodamine filter.
Lineage separation: Patients were studied at a single timepoint prior to DLI and serially post-DLI using short tandem repeat polymerase chain reaction (STR-PCR) to assess chimaeric status in unseparated bone marrow (BM) and peripheral blood (PB) and when possible in selected lineages. For lineage specific analyses, 3-5 ml of BM and 10 ml of PB were separated into mononuclear and granulocyte fractions by Ficoll-Hypaque density gradient centrifugation. In the first patient UPN 011/86, lymphocyte-enriched fractions were obtained using a plastic adherence assay. Mononuclear cells were incubated in RPMI supplemented with 10% FCS at 37°C for 2 h and the non-adherent lymphocyte-enriched fraction was removed. In UPN 006/88, UPN 004/94 and UPN 013/93, CD2-positive T cells were isolated from the mononuclear cell fraction using Dynabead separation according to the manufacturer's recommendations (Dynal, Oslo, Norway). In UPN 013/93 the CD34-positive cell fraction was also isolated using Dynabeads (Dynal). In-house assessment of the purity of the Dynabead separation procedure indicated a purity of 99.0-99.9% in the positively selected fraction (data not shown).
Lineage-specific STR-PCR: DNA was extracted from BM and PB fractions using a standard SDS/proteinase K extraction. DNA was amplified using a panel of five STR primers as previously described. 15, 16 Radiolabelled ␣ 32 P-dCTP was incorporated into the PCR. Following amplification, samples were electrophoresed on an 8% denaturing polyacrylamide sequencing gel and results were analysed after exposing the gel to autoradiography for 4-24 h. The routine sensitivity of the STR-PCR technique is 0.1-0.01%. 15, 16 The STR-PCR assay is a semiquantitative one, significant increases or decreases in donor or recipient cell populations can be identified from analysis of serial samples. All results are confirmed using a second polymorphic STR-PCR marker and results are analysed by two independent observers.
Definitions: Aplasia was defined as a hypocellular marrow and peripheral blood cytopenia: platelets Ͻ20 × 10 9 /l, total neutrophil count (TNC) Ͻ0.5 × 10 9 /l. Acute GVHD was graded and chronic GVHD was classified according to standard criteria. 17, 18 A haematological remission was defined as the absence of signs and symptoms of CML, a TNC у2 × 10 9 /l, haemoglobin у11 g/dl, platelets у50 × 10 9 /l and normal bone marrow cellularity with an absence of the Ph chromosome by standard cytogenetic analysis.
The degree of chimaerism observed was defined as follows: D, donor chimaerism, 95-100% of cells were donor in origin; MR, mixed predominantly recipient, Ͼ90% of cells were of recipient origin; MC, mixed chimaera, cells ranged from Ͻ90% recipient to Ͼ10% recipient in origin; MD, mixed predominantly donor cells ranged from Ͼ90% to Ͻ95% donor in origin. 
Results
Clinical outcome post-DLI
A full haematological remission was induced in all four patients, although follow-up is very short in UPN 013/93. The first clinical indication of a GVL response in UPN 011/86 was the appearance of grade 1 skin GVHD on day 51. This coincided with a decline in the haemoglobin level (Hb) to 8.9 g/dl. A transient marrow aplasia ensued ( Figure  1a) . A haematological remission, as defined, was seen by day 98. In UPN 006/88 the development of acute GVHD (skin, grade 1) was the first indicator of a GVL response (day 64) (Figure 1b) . UPN 004/94 showed bone marrow morphological evidence of progression from cytogenetic relapse to haematological relapse when evaluated at day 15 and day 42 post-DLI before subsequently responding to DLI. STR-PCR analysis of the total BM fraction at this time showed no indication of a molecular response ( Figure  2 ). Both UPN 006/88 and UPN 004/94 had a transient fall in white cell and platelet counts but did not develop aplasia 
Chimaerism prior to DLI therapy
STR-PCR analysis of the total BM fraction in each of four patients indicated the presence of 1-40% donor cells prior to DLI. UPN 011/86 had approximately 5% donor cells present in the total BM fraction. Lineage-specific chimaerism prior to DLI was not performed. Analysis in UPN 006/88 indicated predominantly recipient haematopoiesis in the total BM fraction (1% donor cells). There was an increased proportion of donor cells in the PB and BM CD2-positive T cell fraction (Figure 1) .
In UPN 004/94 at the time of relapse, 40% of metaphases analysed were Ph-positive and recipient in origin. STR- 
Monitoring of lineage-specific chimaerism post-DLI
Serial STR-PCR of the total BM fraction in all four patients illustrated the conversion from mixed chimaerism to predominantly donor profile. In UPN 011/86 the first evidence of molecular conversion to donor haematopoiesis was the PB lymphocyte-enriched fraction which converted to a predominantly donor profile on day 70 (Figure 1a) . A change in the BM fractions was subsequently observed with complete conversion to donor chimaerism by day 91 ( Figure  1a) . At day 84, both the monocyte-and lymphocyteenriched fractions were fully donor in origin, however the total BM and PB fractions still had a minor population of recipient cells present. CFU-GM colonies cultured from the bone marrow mononuclear cells at this time were all donor in origin (data not shown). UPN 006/88 showed a conversion from mixed to donor chimaerism between day 70-98 post-DLI (Figure 1b) . The PB CD2-positive fraction was the first lineage to convert from a predominantly donor to a fully donor profile at day 70 (Figure 1b) . At day 91, the PB and BM granulocyte fraction was predominantly recipient in origin while the other lineages had converted to a donor profile. The granulocytes converted to a donor profile by day 98. A similar pattern of conversion was observed in UPN 004/94 ( Figure  1c ). Analysis at day 42 showed that the PB CD2-positive fraction was predominantly donor while the other lineages were predominantly recipient in origin (Figure 2) .
In UPN 013/93 lineage analysis showed a predominantly donor profile prior to the first DLI. At day 35 post-first infusion, the BM lineages had become predominantly recipient in origin in contrast to the PB fractions which were predominantly donor ( Figure 3) . The total BM/PB, granulocytes and CD34 + fraction in both the BM and PB remained predominantly recipient in origin between days 98-105 post-first DLI. The BM CD2
+ fraction showed an increase in donor profile while the PB CD2 + cells remained mixed, predominantly donor. The first evidence of response following the second DLI was seen at day 70 when the PB CD2-positive fraction became Ͼ95% donor, while the other lineages remained mixed, predominantly recipient. Assessment of the BM lineages were not possible because the patient declined to have any BM aspirates taken during this time. Analysis at day 91 and day 98 showed the conversion of the mononuclear lineages to full donor chimaerism while the granulocyte fraction remained predominantly donor in origin.
Discussion
The successful manipulation of the anti-leukaemic GVL response through infusion of donor lymphocytes for relapsed CML has realised its initial potential with response rates of up to 80% reported for CML. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Despite the success and increased use of donor T cell infusions to treat leukaemic relapse post-BMT, the mechanism and the kinetics of the GVL response are poorly understood. The timing of response to DLI varies widely from patient to patient, with responses as early as 4 weeks 4 and late responses (52-54 weeks) reported. 9, 10 Therefore in managing DLI therapy on an individual patient basis, it would be useful to have reliable early indicators of the probable outcome. In this study we have used molecular measurements of haematopoietic chimaerism to identify possible indicators of the GVL response post-DLI and the development of aplasia.
The development of acute GVHD in three of the four patients was the earliest clinical indication of a GVL response. In UPN 011/86 and UPN 013/93 a fall in haemoglobin preceded the fall in platelet and white cell counts and was the first haematological indicator of a response. Molecular analysis of enriched fractions post-DLI in UPN 011/86 indicated that the PB lymphocyte-enriched fraction was the first lineage to convert to a donor profile ( Figure  1a ). At this time MacKinnon et al 10 reported mixed T cell chimaerism in patients prior to DLI with conversion to full donor T cell chimaerism in remission patients following a GVL response. To investigate this finding further we isolated cell fractions from our subsequent patients using Dynabead separation to yield a cell fraction with a higher purity. STR-PCR of these highly purified populations indicated that the CD2-positive fraction (CD2 + ) in UPN 006/88 and UPN 004/94 converted to a predominantly donor profile before the other lineages.
In UPN 013/93 no clinical evidence of a GVL response was seen following the first lymphocyte infusions. The BM CD2
+ fraction, in contrast to the other lineages, showed an increased percentage of donor cells at day 98 and 105, while the PB CD2 + fractions remained predominantly donor (Figure 3 ). This may have been an indicator of a response, however, the clinical evidence of disease progression prompted the initiation of a second round of DLI. Following the second dose of DLI the PB CD2 + fraction indicated a response when the other lineages showed no change or progressive mixed chimaerism (Figure 3) .
These preliminary lineage-specific results indicate that A complication of the use of DLI is the development of aplasia. Aplasia presumably occurs when the residual pool of donor cells is insufficient to repopulate the bone marrow after the elimination of the leukamic cells by the GVL effect. Chimaerism analysis prior to DLI in our study indicated that donor cells persisted in the total BM fraction in all four patients. Aplasia was seen only in UPN 011/86 and was transient in nature. Lineage-specific analysis identified mixed T cell chimaerism in the BM and/or PB in three patients studied prior to DLI. Both fully donor and mixed T cell chimaerism prior to DLI has been reported by other groups. 6, 10, 11, 19, 20 However, the degree of T cell chimaerism prior to DLI is not a useful predictor of the risk of developing aplasia.
The analysis of the CD34-positive fraction in UPN 013/93 at the time of relapse indicated that the CD34 + cells were donor in origin. Disease progression was seen following the initial DLI dose, during which time the CD34 + fraction became predominantly recipient. Following a second dose of DLI, the CD34 + fraction became fully donor, with no evidence of aplasia. Recently Keil et al 20 reported a significant percentage of donor CD34 + cells in 4/7 patients prior to DLI. None of these patients developed aplasia whereas two patients without donor CD34 + cells had prolonged aplasia. These observations indicate that the chimaeric state of CD34 + fraction may be a useful indicator of donor stem cell reserve prior to DLI and may identify those patients at risk of developing aplasia post-DLI.
Molecular analysis of specific haematopoietic lineages can also aid in understanding the kinetics of the GVL process; eg in UPN 011/86, the lymphocyte fraction and the CFU-GM colonies cultured from the bone marrow mononuclear cells at day 84 were fully donor in origin, while the total PB and BM fractions showed mixed chimaerism (Figure 1a ). This presumably implies that a population of mature granulocytes of recipient origin was present in the total PB and BM fractions. The slower conversion of the granulocyte fraction was confirmed in the other three patients and has been reported by other groups. 4, 19 The persistence of the granulocytic fraction could be purely quantitative as the granulocyte progenitor pool is expanded in chronic phase CML. 21 Alternatively, the granulocytes may be more resistant to T cell-mediated cytotoxic cell death leading to their slower elimination.
The STR-PCR-based assay gave an early indication of response in all four patients and was particularly useful during the cytopenic phase when metaphase analysis was not possible. FISH analysis in UPN 004/94 corresponded well to the STR-PCR assay and confirmed the kinetics of the response. Qualitative RT-PCR for the detection of BCR-ABL mRNA remained positive until analysis at 6 months post-DLI in three patients tested (data not shown) and was not a useful early indicator of response, particularly during the potential cytopenic phase. Quantitative RT-PCR can detect a reduction in the number of BCR-ABL transcripts following DLI. 11, 19 However, STR-PCR provides a more robust DNA-based assay which has the ability to detect subtle quantitative changes in degrees of chimaerism in specific lineages when marrow hypoplasia and peripheral cytopenia is occurring.
The harnessing of the anti-leukaemic effect of donor lymphocyte infusions has the potential to open many new options for allogeneic bone marrow transplantation. The reemergence of T cell depletion of BM grafts to prevent GVHD coupled with the use of DLI to treat minimal residual disease or the genetic manipulation of T lymphocytes with suicide genes which potentially enable the T cell response to be switched off when a detrimental GVHD reaction develops, are some of the novel approaches now reaching clinical application. 22, 23 The monitoring of T cell chimaerism as an early marker for response using STR-PCR should be of benefit in monitoring new DLI therapy protocols, particularly in dose escalation studies for the treatment of molecular or cytogenetic relapse, where an early response indicator may eliminate the need for further infusions of T cells. The detailed monitoring of these new immunotherapeutic approaches at the molecular level should also increase the understanding of the effectors, mechanism and the kinetics of the GVL reaction.
